PRNewswire

Ribociclib (Kisqali) plus aromatase inhibitor (AI) recommended for HR+/HER2- early breast cancer (EBC) node-positive and high-risk node-negative patients, as studied in the NATALEE trial and indicated by the FDA1 Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: